# Medical Oncology (gastrointestinal) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lorraine Hansberry (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML034-SYN
- Date: 2026-05-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Samuel Adeyemi-Rourke, MD
- Calendar frame: modern shifted

- Requested by: Odette Marchetti-Fields, MD

## Reason for consultation

Suspected pancreatic or duodenal cancer in a 32-year-old playwright with two months of epigastric pain boring through to the back, a 5 kg weight loss, black stools with iron deficiency anemia (hemoglobin 9.1 g/dL, ferritin 6 ng/mL), new diabetes (A1c 6.6%) and a cholestatic liver pattern. Upper endoscopy and pancreas-protocol CT are booked this week. Please see her within two weeks to review the results with her and plan treatment if cancer is found. **S**

## History

Ms. Hansberry, 32, is seen at the request of Dr. Marchetti-Fields two weeks after she presented with two months of epigastric and back pain, weight loss, black stools with iron deficiency anemia, and new diabetes. Since then she has had an upper endoscopy, a pancreas-protocol CT, an endoscopic ultrasound with biopsy and a biliary stent, two doses of intravenous iron, and review at our pancreatic tumor board. The pain is 6 out of 10 and breaks her sleep; her stools are pale and float after fatty meals; there has been no black stool since the iron. She works at home as a playwright and is active most of the day (ECOG 1). She is not pregnant and has no children. She asked for the facts in plain words. **S**

## Examination

| System | Finding |
|---|---|
| General | Thin, tired, composed; weight 55.4 kg; blood pressure 108/68, pulse 92; ECOG 1 |
| Eyes | Slight scleral icterus, less than at the first visit |
| Abdomen | Epigastric tenderness without guarding; no mass, liver enlargement or ascites |
| Lymph nodes | No supraclavicular nodes; no umbilical nodule |

BP 108/68 mmHg; pulse 92 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 55.4 kg; BMI 20.9 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Marchetti-Fields's intake note and results. Upper endoscopy: an ulcerated, oozing mass on the medial wall of the second part of the duodenum beside the papilla, no peptic ulcer; biopsies: adenocarcinoma infiltrating from the pancreas. Pancreas-protocol CT with CT of the chest: 3.1 cm hypoattenuating mass in the pancreatic head invading the duodenum; common bile duct 13 mm and pancreatic duct 5 mm; contact with about 200 degrees of the superior mesenteric vein with short-segment narrowing that can be reconstructed; no contact with the superior mesenteric artery, celiac axis or common hepatic artery; no liver, peritoneal or lung lesion. EUS-guided biopsy: pancreatic adenocarcinoma, moderately differentiated; extra cores held for molecular profiling. ERCP: fully covered metal stent across a distal bile duct stricture. Today: bilirubin 0.9 mg/dL, alkaline phosphatase 168 U/L, CA 19-9 486 U/mL (after drainage), CEA 3.9 ng/mL, hemoglobin 10.4 g/dL, neutrophils 4.6, platelets 366, creatinine 0.68 mg/dL, albumin 3.5 g/dL, fasting glucose 141 mg/dL, INR 1.0. Hemoglobin: 10.4 g/dL (low); White cell count: 7 10*3/uL; Absolute neutrophil count: 4.6 10*3/uL; Platelets: 366 10*3/uL; Creatinine: 0.68 mg/dL; eGFR (CKD-EPI 2021): 119 mL/min/1.73 m²; Glucose: 141 mg/dL (high); ALT: 30 U/L; AST: 28 U/L; Alkaline phosphatase: 168 U/L (high); Total bilirubin: 0.9 mg/dL; Albumin: 3.5 g/dL; CA 19-9: 486 U/mL (high); CEA: 3.9 ng/mL (high); INR: 1; PHQ-9: 7; GAD-7: 8; Pain score (0 to 10): 6. All results are synthetic.

## Assessment

1. **Adenocarcinoma of the head of the pancreas, borderline resectable** (C25.0). Pancreatic ductal adenocarcinoma of the head of the pancreas invading the duodenum, which explains the bleeding, the anemia, the obstructed bile and pancreatic ducts, the pain and the new diabetes. By NCCN criteria it is borderline resectable, because the tumor contacts more than half the circumference of the superior mesenteric vein, although the vein can be reconstructed and no artery is involved; there is no distant spread on CT. For borderline resectable disease, chemotherapy first is preferred over going straight to surgery: it treats cancer that may already have spread unseen, can shrink the tumor away from the vein, and shows whether the cancer is controlled before a major operation. She is young and fit, with normal kidney function and bilirubin now normal, so modified FOLFIRINOX is the regimen of choice. The aim is cure, and surgery after chemotherapy offers the best chance of it; she was also told honestly that pancreatic cancer often returns even after successful surgery. **S**
2. **Diabetes due to the pancreatic cancer** (E08.9). New diabetes with weight loss at her age is caused by the cancer (type 3c), not type 2. It may worsen after removal of the head of the pancreas, and insulin is the treatment if glucose-lowering is needed; dexamethasone should be limited. **S**
3. **Exocrine pancreatic insufficiency** (K86.81). Pale floating stools and weight loss with a blocked pancreatic duct: start enzyme replacement now on clinical grounds, without waiting for a stool test. **S**
4. **Cancer-related pain** (G89.3). Moderate tumor pain; low-dose opioid with a bowel regimen first, and EUS-guided celiac plexus neurolysis if it becomes severe. **S**

## Recommendations

1. Modified FOLFIRINOX every two weeks for six cycles (about three months) before surgery, through a port: oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2 and fluorouracil 2400 mg/m2 over 46 hours, with pegfilgrastim on day 3; dose reductions for toxicity rather than delays where possible.
2. Restaging with CA 19-9 every two cycles and pancreas-protocol CT after four and after six cycles; tumor board review after restaging, and pancreaticoduodenectomy with vein resection if there is no progression.
3. Chemotherapy after surgery to complete about six months of treatment in all, the regimen chosen by her tolerance and the pathology.
4. Germline multigene panel after genetic counseling, as for every patient with pancreatic cancer, and tumor molecular profiling on the EUS cores; cascade testing for blood relatives only if a germline variant is found.
5. Hepatitis B, hepatitis C and HIV screening and a pregnancy test before cycle 1; PCV20 and recombinant zoster vaccine now, before chemotherapy; no live vaccines.
6. Antiemetic prevention with fosaprepitant, palonosetron, one day of dexamethasone and olanzapine on days 1 to 4, sparing further dexamethasone because of her diabetes; loperamide teaching for irinotecan diarrhea; neuropathy checks before each oxaliplatin dose.
7. Palliative care from now, alongside cancer treatment; oxycodone 5 mg as needed with senna; pancrelipase about 72,000 lipase units with meals and half that with snacks; dietitian review.
8. Home glucose monitoring, no glucose-lowering drug for now, insulin after surgery if needed; dilated eye examination and urine albumin at diagnosis of diabetes.
9. Khorana score 3: prophylactic apixaban 2.5 mg twice daily once the duodenal bleeding has settled for several weeks; enoxaparin for four weeks after surgery.
10. Fertility counseling before chemotherapy; effective non-estrogen contraception during treatment.
11. Primary care to share the monitoring: blood counts and glucose at visits, mood and distress screening, weight, and help with symptoms between oncology visits.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Marchetti-Fields the same day and presented at the pancreatic tumor board with surgery, radiology and pathology. The images and biopsy results were explained to Ms. Hansberry in plain words, with the aim of treatment and its uncertainty; she chose to start chemotherapy without delaying for fertility preservation. She decides who else receives this note. **S**

## Follow-up

Port placement next week; cycle 1 in two weeks; oncology review before each cycle; restaging after cycles 4 and 6; Dr. Marchetti-Fields continues primary care and shares the monitoring. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026), National Comprehensive Cancer Network
- Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016), American Society of Clinical Oncology
- Khorana AA, et al. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. J Clin Oncol 2019;37(23):2082-2088 (PMID 31180816) (2019), American Society of Clinical Oncology
- Stoffel EM, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2019;37(2):153-164 (PMID 30457921) (2019), American Society of Clinical Oncology
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024), American Society of Clinical Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023), American Society of Clinical Oncology
- Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (PMID 32658626) (2020), American Society of Clinical Oncology
- Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020;38(31):3698-3715 (PMID 32716741) (2020), American Society of Clinical Oncology
- Oktay K, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018;36(19):1994-2001 (PMID 29620997) (2018), American Society of Clinical Oncology
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026), American Diabetes Association
